ライフサイエンスコーパス: pegylation

1 tion with poly(ethylene glycol) chains (i.e. PEGylation).

2 es of select cysteines using the kinetics of pegylation.

3 (LLP2A-DOTA)(4)PEG(10,000) were prepared by PEGylation.

4 of PEG moieties attached, and the site(s) of PEGylation.

5 -like liposomes with reduced cholesterol and pegylation.

6 ed independent confirmation of the extent of pegylation.

7 resent in the circulation were unaffected by PEGylation.

8 e extended plasma half-life achieved through pegylation.

9 , with improved stability of insulin through PEGylation.

10 of peptides does not recur upon the peptide PEGylation.

11 ndrimers with pH-sensitive bonds and surface PEGylation.

12 o be used for highly efficient site-specific PEGylation.

13 ood retention time was markedly prolonged by PEGylation.

14 s predicted from individual N- or C-terminal PEGylation.

15 thus serving as a potential alternative for PEGylation.

16 a defined molecular weight (dispersity-free) PEGylation agent.

17 cation reactions during the synthesis of the PEGylation agents, and facilitates straightforward ident

18 ng aspect of PEGylation is the dispersity of PEGylation agents, which results in batch-to-batch varia

19 PEGylation also reduced the immunogenicity of rMETase.

20 Pegylation also reduced the tendency of the conjugate to

21 ated the proposed interface by site-directed PEGylation and by swapping the a1-loop in pseutarin C wi

22 omplexed nucleic acid nanoparticles, such as PEGylation and charge repulsion, typically arrest the ve

23 We combined both PEGylation and circularization by exploiting two distinc

24 ecular suture that allows both site-specific PEGylation and covalent closure.

25 nded the plasma half-life of the peptide via PEGylation and demonstrated effective FXIa inhibition ov

26 Simultaneous PEGylation and fluorescent labeling of sCT is also demon

27 the SMOF NP can be easily customized (e.g., PEGylation and ligand conjugation) via various functiona

28 Protein PEGylation and PEG chain elimination occurred without ch

29 two pharmaceutical modification techniques: PEGylation and Polylactic glycolic acid (PLGA) microenca

30 lpha molecule that is related to the site of pegylation and size of polyethylene glycol (PEG) attache

31 en perform a comparative study on the random PEGylation and subsequent characterisation of the protei

32 Using biogenic intermediates, mass tagging (pegylation), and a molecular tape measure, we explored t

33 asma pharmacokinetics with carboxyl-directed pegylation, and (ii) enable transport through the BBB by

34 ultiple attachment sites, solubility through PEGylation, and drug release through the use of pH-sensi

35 A chemistry, linkers, conjugation chemistry, PEGylation, and drug-to-antibody ratios (DARs) for their

36 rom peptides already modified by lipidation, PEGylation, and Fc fusion could produce ultralong-acting

37 we discuss the current status of lipidation, PEGylation, and Fc fusion technologies to obtain long-ac

38 , incorporation of noncanonical amino acids, PEGylation, and lipidation) alongside advancements in de

39 oped that when combined with methods such as pegylation antibody Fc attachment and binding to serum a

40 tal problems with the existing approaches to PEGylation are inefficient conjugation and the formation

41 s and Pluronics) and advances in the area of PEGylation as the most important bioconjugation strategy

42 First, PEGylation assays revealed that the AAP did not undergo

43 PEGylation assays using a cysteineless version of ArnT s

44 trast, after intravenous injection, targeted PEGylation at HVRs 1, 2, 5, and 7 increased viral liver

45 PEGylation at the C terminus retained the in vitro activ

46 PEGylation at Val-1(alpha) and at Val-1(beta) increase t

47 ich is at a higher level than that caused by PEGylation at Val-1(beta).

48 AM radicals can be easily derivatized (e.g., PEGylation) at the nine carboxylate groups and the resul

49 Initial pegylation attempts using lipid-poor apoAI showed a mark

50 onally designing conjugates while preserving PEGylation benefits.

51 In vitro, PEGylation blocked uptake of viruses via the Kupffer cel

52 on improves stability in a manner similar to PEGylation, but that the new conjugates retain or even i

53 reported approach breaks the limitations of PEGylation by the proactive prevention of ADAs.

54 Therefore, the pattern of PEGylation can be manipulated for the design of the PEGy

55 If PEGylation can be proved to promote evasion of microglia

56 Accordingly, the sites of PEGylation can determine the tetramer stability of the P

57 Results demonstrate that PEGylation can significantly improve the therapeutic ran

58 cation of proteins with polyethylene glycol (PEGylation) can increase plasma half-lives, stability, a

59 Depending on the PEGylation chain length (n), Mito-PEG-ATO analogs inhibi

60 upled to each subunit of rMETase after hyper-PEGylation compared with 6-8 PEG chains attached to the

61 PEGylation completely abrogated coxsackievirus and adeno

62 Furthermore, after PEGylation, ConA's binding affinity to the fluorescent c

63 Thus, the molecular modification of PEGylation confers critical new properties to rMETase fo

64 Using confocal microscopy, we show that PEGylation constrains molecules outside the T-tubule net

65 of beta receptor subunit binding by adjacent PEGylation could be responsible for the altered biologic

66 Site-specific PEGylation could be used more generally to engineer cyto

67 PEGylation decreased the transfection efficacy by at lea

68 tio, hydrophobe (BMA) placement, and surface PEGylation density was correlated to important outcomes

69 d corona-forming polymers (indirectly tuning PEGylation density) and identification of a ternary nano

70 Although PEGylation did extend the beta-elimination circulation h

71 irmed the assigned structure and showed that pegylation did not disrupt the hydrogen-bonded ridge-til

72 the pharmacokinetic profiles, indicate that PEGylation does protect the virus from inactivation in t

73 PEGylation dramatically increased Gal3C thermal stabilit

74 The design of the extension arm-facilitated PEGylation (EAFP) of proteins takes advantage of the hig

75 n termed "PEG-fluorochrome shielding", where PEGylation enhances quantum yields while blocking troubl

76 ication of drug structure (i.e., lipidation, PEGylation, etc.), and mucoadhesive materials in the for

77 grafting polyethylene glycol onto particles (PEGylation) extend circulation times; however, these par

78 PEGylation extended the circulation half-life of active

79 tilizing bioengineering techniques including PEGylation, Fc fusion, and single-chain design.

80 ution study showed that LCP-II required more PEGylation for MPS evasion than the previous LPD, probab

81 rated in liposomes with different degrees of pegylation (FosPEG 2% and FosPEG 8%), following i.v. adm

82 esults of the present study demonstrate that PEGylation greatly prolongs serum half-life of the rMETa

83 The PEGylation had minimal effect on integrin-binding affini

84 Previously, PEGylation has been shown to improve antibiotic penetrat

85 PEGylation has been shown to increase the residence time

86 While PEGylation has been widely used to reduce host immune re

87 Subunit stabilization and PEGylation has thus produced a potential protein therape

88 PEGylation has turned proteins into important new biopha

89 ng of polyethylene glycol (PEG) to proteins (PEGylation) has become a standard method to prolong bloo

90 ng the polymer polyethylene glycol (PEG), or PEGylation, has brought more than ten protein drugs into

91 pulsion-based entropic stabilization-such as PEGylation-has long been the dominant strategy for desig

92 ion technologies including glycosylation and PEGylation have been developed to improve its pharmacoki

93 tion of the non-specific interaction via the PEGylation; (iii) tumor targeting via the MMP2-mediated

94 cuss how modification of the FUD peptide via PEGylation impacts pharmacokinetic profiles of the FUD p

95 Here, we show that pegylation improved the pharmacokinetic and therapeutic

96 This is often achieved via PEGylation in protein-based therapies, but it remains ch

97 lysine groups on the surface of ConA (i.e., PEGylation) in an attempt to improve its stability in th

98 In addition, we show that PEGylation increases protein adsorption with our formula

99 three types of (198)Au-GNPs with or without PEGylation into mice; the gamma radiation in blood speci

100 PEGylation is a promising approach to address the centra

101 PEGylation is a proven approach to prolonging the durati

102 Site-specific PEGylation is achieved with a bis-thiol alkylating PEG r

103 PEGylation is an attractive approach to modifying oligon

104 PEGylation is by far the most common method employed to

105 PEGylation is routinely used to extend the systemic circ

106 A challenging aspect of PEGylation is the dispersity of PEGylation agents, which

107 ly(ethylene glycol) (PEG) conjugation (i.e., PEGylation) is a commonly used strategy to increase the

108 Polyethylene glycol conjugation (PEGylation) is the most successful strategy to date to o

109 lycol) (PEG) to therapeutic agents, known as PEGylation, is a well-established strategy for enhancing

110 e prepared purified, homogeneous, positional pegylation isomers of IFN-alpha2b that were monopegylate

111 Pegylation led to more mitochondrial localization as sho

112 Initial results suggest that hyper-PEGylation may become a new strategy for PEGylation of p

113 ctivity and increased PEG size suggests that pegylation may interfere with interaction and binding of

114 entional methods often lead to heterogeneous PEGylation mixtures with reduced protein activity.

115 residues; our observations here suggest that PEGylation near such locations might be a useful strateg

116 However, the effect of PEGylation needs to be carefully studied due to the obse

117 Chemical shift data suggest that pegylation occurs mainly at the N(delta)(1) position in

118 hydroxy-,N(omega)-methoxy-carbamoylation and pegylation of 4Aph at positions 5 and 6 (7-10, 15-17, 22

119 Taken together, these results suggest that pegylation of a polymer-photosensitizer conjugate improv

120 PEGylation of a protein can be completed in 24 h and pur

121 s is the first demonstration of non-covalent PEGylation of acylated peptides, an important biologic c

122 dition of ribavirin to alpha interferon, the pegylation of alpha interferon, and the demonstration th

123 PEGylation of an oligonucleotide using a brush polymer c

124 Pegylation of apoAI in rHDL markedly increases its plasm

125 fe in the circulation, we determined whether pegylation of apoAI or HDL would increase its plasma hal

126 PEGylation of biologics offers enhanced stability, durat

127 Therefore, the PEGylation of ConA can overcome major hurdles for ConA-b

128 e have successfully applied this approach to PEGylation of cytokines, enzymes, antibody fragments and

129 Pegylation of full-length Kv1.3, as well as Kv1.3 fragme

130 PEGylation of Hb at Cys-93(beta) perturbed the heme envi

131 In contrast, PEGylation of Hb at Val-1(beta) gives rise to less prono

132 PEGylation of human FGF21 at a specific and preferred si

133 However, pegylation of human holo-HDL or reconstituted phospholip

134 We hypothesized that PEGylation of IL-15 interferes with beta but not alpha r

135 Pegylation of introduced cysteines shows that the pore h

136 which lipid binding seems to protect against pegylation of key functional residues.

137 For site-specific PEGylation of LMB-2, one cysteine residue was introduced

138 In this study, we evaluated the effect of PEGylation of mesoporous silica nanorods (MSNR) on hemol

139 t DNA technology, site-directed mutagenesis, pegylation of molecules, peptide library screening, and

140 restingly, mechanistic studies indicate that PEGylation of nanoparticles does not reduce dendritic ce

141 Pegylation of nanoparticles has been widely implemented

142 reporter fusions and sulfhydryl labelling by PEGylation of novel cysteine residues introduced into a

143 PEGylation of NP was done by including a PEG-phospholipi

144 This study showed that PEGylation of paclitaxel offers a potential delivery sys

145 PEGylation of peptides and proteins has been widely used

146 PEGylation of peptides and proteins presents significant

147 per-PEGylation may become a new strategy for PEGylation of protein biologics.

148 PEGylation of protein side chains has been used for more

149 Because pegylation of purified proteins is commonly used as a me

150 Site-specific PEGylation of recombinant immunotoxins may increase thei

151 PEGylation of residues within our proposed binding site

152 PEGylation of residues within the a1-loop also reduced t

153 in vivo half-life depended on the extent of PEGylation of rMETase.

154 d for the successful site-specific and rapid pegylation of sCT.

155 PEGylation of subtilisin-A (Sub-A) was performed by atta

156 with small unilamellar vesicles (SUVs), 10% PEGylation of the formulation could influence liposome r

157 led FUD and FUD conjugates demonstrated that PEGylation of the FUD peptide enhanced blood exposure af

158 PEGylation of the glycine-serine linker was used to enha

159 PEGylation of the photosensitizer construct was found to

160 PEGylation of the RTNs enhanced luciferase transfection

161 PEGylation of therapeutic agents is known to improve the

162 ns of MW similar to that of PEG, used in the PEGylation of therapeutic proteins, can be employed.

163 PEGylation of this ChABC mutant inhibited unfolding and

164 We performed random TMS(PEG)12 PEGylation of tTF-NGR to improve the antitumor profile o

165 The PEGylation of very low O2 affinity Hbs is now contemplat

166 nized with neutralizing anti-VSV antibodies, PEGylation of VSV improved the persistence of VSV in the

167 Pegylation of wortmannin and 17-hydroxywortmannin gives

168 ormed a molecular recognition of DCL- and AG-PEGylation on ligand binding on PSMA active site.

169 A negative effect of PEGylation on MTX loading was observed but PEGylated MSN

170 bination of reduced vesicle size and surface pegylation on the biodistribution and adjuvanticity of t

171 ut could do little to identify the extent of pegylation or to support characterization of the consist

172 sing a microfluidic system) in analyzing the pegylation pattern of a recombinant protein over a range

173 teine-scanned S6 transmembrane segment using pegylation (PEG-MAL) and calmodulation (CaM-MAL).

174 sic, and 1,20-eicosanedioic acid showed that pegylation per se has little, if any, effect on carboxyl

175 The mild, biorthogonal PEGylation preserves Hb's O(2)-binding functionality and

176 We found that PEGylation prevented dose-dependent hemolysis in the con

177 s work illustrates a novel means of specific PEGylation, producing FGF21 analogs with high specific a

178 Pegylation prolongs the serum concentration of IL-10 wit

179 The PEGylation protected subtilisin-A from autolysis at neut

180 tion of antibodies for fluorescent labeling, PEGylation, protein cross-linking, immunoliposome format

181 Our PEGylation protocol solves these problems by exploiting

182 Size exclusion strategy using ligand PEGylation provides a unique approach to evaluate the re

183 A novel traceless reversible protein PEGylation reagent is developed based on thioester chemi

184 We also report that PEGylation reduced, but did not eliminate, the populatio

185 For example, PEGylation reduces the immunogenicity of protein cage-ba

186 Although PEGylation reduces the immunogenicity of protein drugs t

187 PEGylation resulted in an approximately 2-log step decre

188 in, Adagen(R), in 1990 marked the new era of PEGylation, resulting in Doxil(R) (doxorubicin in PEGyla

189 The pegylation results in lower in vitro specific activity a

190 ts of NP size, shape, surface modifications (PEGylation, self-peptide, other polymers), and protein p

191 Finally, PEGylation showed a reduction in electrostatic-induced a

192 light scattering measurements indicate that PEGylation significantly improved ConA's thermal stabili

193 ectly predicts the location of a stabilizing PEGylation site within the chicken Src SH3 domain.

194 owever, in the absence of a specific protein PEGylation site, chemical conjugation is inherently hete

195 potency and in vivo efficacy and provides a PEGylation site.

196 We hypothesize that globally optimal PEGylation sites are characterized by the ability of the

197 developed a method to increase the number of PEGylation sites in a model protein, recombinant methion

198 thereby may prove an alternative to covalent PEGylation strategies.

199 The site of pegylation strongly influenced activity relative to an I

200 their surface shielding through Pt-S-bonded PEGylation synergistically contributed to create catalyt

201 he possibility of using modern site-specific PEGylation techniques to install PEG oligomers at predet

202 after being taken by tumor cells, along with PEGylation technology, ultimately resulted in the timely

203 into the T1-T1 interface had lower rates of pegylation than cytosolic-facing cysteines, namely, C5 i

204 and the anti-IL-17A Fab' benefited more from PEGylation than the anti-IL-13 Fab' did.

205 PEGylation (the covalent attachment of one or more poly(

206 tribution of sites on proteins available for PEGylation (the N terminus and the -amino group of lysin

207 PEGylation, the conjugation of poly(ethylene glycol) (PE

208 elivery strategies, including self-assembly, PEGylation, the enhanced permeability and retention effe

209 culating XTEN-AnxA5 without the necessity of PEGylation, thereby simplifying the synthesis while avoi

210 We demonstrate that after surface pegylation, these silica-coated magneto-fluorescent supe

211 iated enzymatic labeling in combination with PEGylation to develop an anti-mouse CD4 scFv-based PET i

212 were chosen in human FGF21 for site-specific PEGylation to ensure that receptor binding regions were

213 on assistant non-washing technique and shell PEGylation to reach high colloidal stability of drug nan

214 Attachment of polyethylene glycol (pegylation) to a polyacetylated conjugate between poly-l

215 itch of the protein material by high surface PEGylation under conservation of the native three-dimens

216 as chemically modified oligonucleotides and PEGylation using linear or slightly branched PEG.

217 d anti-IL-13 Fab' fragments in the lungs but PEGylation was able to prolong their presence in both th

218 PEGylation was evaluated as a novel strategy for prolong

219 created to improve catalytic efficiency, and PEGylation was used to prolong systemic exposure.

220 achment of long chained polyethylene glycol (PEGylation) was pursued.

221 To increase the extent of PEGylation, we have developed a method to increase the n

222 ral protein modification technologies beyond PEGylation were also highlighted.

223 methoxypoly(ethylene glycol) (mPEG), termed PEGylation, which has led to several clinically approved

224 esidues for antiviral activity and show that pegylation, which often increases a peptide's serum t(1/

225 nt blood-brain barrier passage of DT through PEGylation, which polarizes the molecule and increases i

226 Screening of variant expression level, PEGylation yield, and functional assay identified severa

227 cific C-terminal or dual (N- and C-terminal) PEGylation, yielding (18)F-FBA-A20FMDV2-PEG28 (4) and (1